Aminothiazole modulators of beta-3-adrenoreceptor
The present invention relates to new aminothiazole modulators of beta-3-adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
1. A compound of structural Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R 1 -R 24 are independently selected from the group consisting of hydrogen and deuterium;
at least one of R 1 -R 24 is deuterium; and
if R 20 -R 24 are deuterium, then at least one of R 1 -R 19 are deuterium.
2. The compound as recited in claim 1 wherein at least one of R 1 -R 24 independently has deuterium enrichment of no less than about 10%.
3. The compound as recited in claim 1 wherein at least one of R 1 -R 24 independently has deuterium enrichment of no less than about 50%.
4. The compound as recited in claim 1 wherein at least one of R 1 -R 24 independently has deuterium enrichment of no less than about 90%.
5. The compound as recited in claim 1 wherein at least one of R 1 -R 24 independently has deuterium enrichment of no less than about 98%.
6. The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of
7. The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 10%.
8. The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 50%.
9. The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 90%.
10. The compound as recited in claim 6 wherein each position represented as D has deuterium enrichment of no less than about 98%.
11. The compound as recited in claim 6 wherein said compound has a structural formula selected from the group consisting of
12. The compound as recited in claim 11 wherein said compound has the structural formula:
13. The compound as recited in claim 11 wherein said compound has the structural formula:
14. The compound as recited in claim 11 wherein said compound has the structural formula:
15. The compound as recited in claim 11 wherein said compound has the structural formula:
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R 1 -R 24 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R 1 -R 24 is deuterium.